Seeking Alpha

Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported...

Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported late yesterday that the FDA's Office of Orphan Product Development has granted seven-year orphan drug exclusivity for Procysbi delayed-release capsules for the management of nephropathic cystinosis. The exclusivity period began on the date of the drug's initial FDA approval, April 30.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)